MedLumics is a medical device start-up that translates the latest technological and scientific developments in the biophotonics field into innovative and quality products for improving quality of life.
MedLumics is employing biophotonic technologies to develop products that improve human living standards.
Medlumics was founded in 2009 by Eduardo Margallo and Jose Rubio. The company is based in Madrid, Spain.
Medlumics flagship product, AblaView®, a unique RF irrigated ablation catheter system that merges photonics and miniaturized optics to guide device placement and directly assess the ablation lesions in real time.
The AblaView system is equipped with sensors that use optical coherence tomography—an imaging technique using light to scan and penetrate a few millimeters of tissue—to directly observe the creation of ablation lesions in the cardiac muscle wall in real time and assure the correct placement of the catheter’s electrodes.
MeduLmics is backed by Asabys Partners, Kurma Partners, VI Partners Swiss Innovation, CDTI Innvierte Economía, Andera Partners, Seroba Life Sciences, Ysios Capital and others. The company raised €18M ($21.8M) in a new round on Feb 11, 2021. This brings MeduLmics' total funding to €73.4M to date.